|
|
 Previous Article | Table of Contents | Next Article 
Characterization of a new non-Hodgkin's lymphoma cell line (NCEB-1) with a
chromosomal (11:14) translocation [t(11:14)(q13;q32)]
DL Saltman, PG Cachia, AE Dewar, FM Ross, AS Krajewski, C Ludlam and CM Steel
Medical Research Council Clinical and Population Cytogenetics Unit, Western
General Hospital, Edinburgh, Scotland, UK.
A new cell line, NCEB-1, was established by Epstein-Barr virus (EBV)
transformation of peripheral blood mononuclear cells from a patient with
centroblastic-centrocytic diffuse lymphoma expressing IgM lambda. The
transformed cells were lymphoblastoid, with many cells showing a
plasmacytoid morphology. The NCEB-1 cells had cytoplasmic Ig (CyIg), with
loss of the surface Ig (SIg) expression. Cytogenetic analysis of the cell
line demonstrated two clones with variations: a hypodiploid clone, with a
complex karyotype including a t(11;14)(q13;q32) similar to the original
tumor cells, and a near tetraploid clone with the same markers. Southern
blot analysis of DNA from the patient's neoplastic cells and NCEB-1
demonstrated identical Ig heavy chain gene rearrangement, confirming the
origin of the cell line. The cell line was not tumorigenic when tested in
an in vitro assay using immunosuppressed mice. NCEB-1 has been in
continuous culture for 9 months and will be valuable for the in vivo study
of non-Hodgkin's lymphoma and EBV transformation.
Volume 72,
Issue 6,
pp. 2026-2030,
12/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Ortega-Paino, J. Fransson, S. Ek, and C. A. K. Borrebaeck
Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference
Blood,
February 1, 2008;
111(3):
1617 - 1624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rudelius, S. Pittaluga, S. Nishizuka, T. H.-T. Pham, F. Fend, E. S. Jaffe, L. Quintanilla-Martinez, and M. Raffeld
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
Blood,
September 1, 2006;
108(5):
1668 - 1676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Lacrima, A. Valentini, C. Lambertini, M. Taborelli, A. Rinaldi, E. Zucca, C. Catapano, F. Cavalli, A. Gianella-Borradori, D. E. MacCallum, et al.
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas
Ann. Onc.,
July 1, 2005;
16(7):
1169 - 1176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Quintanilla-Martinez, T. Davies-Hill, F. Fend, J. Calzada-Wack, L. Sorbara, E. Campo, E. S. Jaffe, and M. Raffeld
Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis
Blood,
April 15, 2003;
101(8):
3181 - 3187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Rose, B. E. Smith, and D. G. Maloney
Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects
Blood,
August 13, 2002;
100(5):
1765 - 1773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Robetorye, S. D. Bohling, J. W. Morgan, G. C. Fillmore, M. S. Lim, and K. S. J. Elenitoba-Johnson
Microarray Analysis of B-Cell Lymphoma Cell Lines with the t(14;18)
J. Mol. Diagn.,
August 1, 2002;
4(3):
123 - 136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
